In Vivo March 1, 2010 vol. 24 no. 2 239-241

October 5, 2013

Synchronization of Cortisol Circadian Rhythm by the Pineal Hormone Melatonin in Untreatable Metastatic Solid Tumor Patients and its Possibile Prognostic Significance
on Tumor Progression

Research Article (download PDF version – complete)

FERNANDO BRIVIO1, LUCA FUMAGALLI1, GABRIELE FUMAGALLI2, SIMONETTA PESCIA2, RINALDO BRIVIO2, GIUSEPPE DI FEDE3, FRANCO ROVELLI2 and PAOLO LISSONI3

1 Surgical Division, Bassini Hospital, Cinisello Balsamo, Milan, Italy
2 Department of Clinical Pathology, S.Gerardo Hospital, Monza, Italy
3 Institute of Biological Medicine, Milan, Italy

*Correspondence: Dr. Paolo Lissoni, Divisione di Radioterapia Oncologica, Ospedale S.Gerardo, 20052 Monza, Milano, Italy; Fax: +390392332284, e-mail: p.lissoni@hsgerardo.org

Abstract
The present study was carried out to evaluate the influence of a short-period IL-2 administration on the efficacy of chemotherapy in metastatic colorectal cancer patients with pretreatment lymphocytopenia, which was defined as a lymphocyte count of less than 1500/mm3.

The study included 144 consecutive metastatic colorectal cancer patients, who underwent chemotherapy with oxaliplatin plus 5-fluorouracil. Lymphocytopenia was seen in 41/144 (28%) patients, who were randomized to receive chemotherapy alone or chemotherapy after a prechemoimmunotherapy with IL-2 (3 MIU twice/day for 3 consecutive days), whereas patients with a normal pretreatment lymphocyte count received only chemotherapy.

A normalization of the lymphocyte number was achieved in 12/19 lymphocytopenic patients pretreated with IL-2. The objective tumor regression rate achieved in patients with a normal lymphocyte count prior to chemotherapy was significantly higher compared to that obtained in lymphocytopenic patients treated with chemotherapy alone (54/103 vs. 3/22, p<0.01), whereas no significant difference occurred between patients with normal lymphocyte count and lymphocytopenic patients pretreated with IL-2 (54/103 vs. 8/19).

This study confirms that pretreatment lymphocytopenia is associated with reduced efficacy of chemotherapy in metastatic colorectal cancer patients. Moreover, it suggests that pretreatment with IL-2 before the onset of chemotherapy may enhance the efficacy of chemotherapy in lymphocytopenic patients. Therefore, the administration of IL-2 before the onset of chemotherapy to improve the immune status of cancer patients may be considered as a new chemoimmunotherapeutic combination, which may be recommended in the treatment of advanced cancer patients, particularly in those with cancer-related immune alterations.

http://www.imbio.it/wp-content/uploads/2013/10/100430_synchronization_cortisol_circadian_rhythm.pdf(download PDF version – complete)

Copyright by IMBIO 2017. All rights reserved.